Global Enteral Feeding Formula Market By Product(Standard Formula, Disease-specific Formulas), By Flow Type(Intermittent Feeding Flow, Continuous Feeding Flow), By Stage(Adults, Pediatrics), By Indication (Alzheimer’s, Nutrition Deficiency, Cancer Care), By End-use(Hospitals, Cardiology, Neurology), By Sales Channel(Online Sales, Retail Sales, Institutional Sales), By Product(Standard Formula, Disease-specific Formulas), By Flow Type(Intermittent Feeding Flow, Continuous Feeding Flow), By Stage(Adults, Pediatrics, By Indication, Alzheimer’s, Nutrition Deficiency), By End-use(Hospitals, Cardiology, Neurology), By Sales Channel(Online Sales, Retail Sales, Institutional Sales) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast; 2024-2033
- Published date: Dec 2023
- Report ID: 32817
- Number of Pages: 248
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
The Enteral Feeding Formulas Market size is expected to be worth around USD 12.3 billion by 2033, from USD 7.2 billion in 2023, growing at a CAGR of 5.5% during the forecast period from 2023 to 2033.
The rising prevalence of diabetes patients is driving the market growth for diabetic disease-specific formula, which is created to fulfill the nutritional needs of certain patient populations. Enteral nutrition formulations are being developed to meet the nutritional requirements of specific patient groups.
For instance, formulas containing higher levels of omega-3 fatty acids are being developed to help prevent inflammation and improve neurological development in premature infants. Additionally, formulas containing more elevated amounts of fiber and complex carbohydrates are being developed to help manage blood sugar levels in patients with diabetes.
Furthermore, formulations containing higher levels of antioxidants and vitamins are being developed to help reduce the risk of cancer and chronic liver disease. Overall, the increasing prevalence of chronic liver diseases, the rising number of premature births, and expanding home care and nursing homes are all expected to drive the demand for enteral nutrition formulas shortly.
*Actual Numbers Might Vary In The Final Report
Key Takeaways
- Market Growth and Projections: Expected market value: By 2033, anticipated worth around USD 12.3 billion, exhibiting a growth from USD 7.2 billion in 2023. Projected CAGR (Compound Annual Growth Rate): Estimated growth rate stands at 5.5% from 2023 to 2033.
- Products: Dominance of Standard Formulas (56.8% market share) catering to general needs, while Disease-specific Formulas cater to specific health conditions.
- Flow Types: Intermittent Feeding Flow (89% market share) and Continuous Feeding Flow cater to different patient tolerances and digestion capacities.
- Stage and Indication: Adults (90.4% market share) and varied indications like Alzheimer’s, cancer care, and diabetes contribute significantly to market segmentation.
- Sales Channels: Institutional Sales (51.6% market share), Retail Sales, and growing Online Sales.
- Drivers of Market Growth: Increasing Cancer Incidence: Demand for enteral nutrition rises with increasing cancer cases, with specialized formulas aiding in reducing infection risks during treatments.
- Challenges: Awareness Gap: Lack of awareness among medical professionals and patients regarding appropriate enteral feeding practices poses a significant restraint on market growth.
- Opportunities: Innovation Potential: Growing market space for companies introducing new products catering to diverse nutritional needs, including high-protein formulas and blends featuring real-food ingredients.
- Regional Analysis: North America: Dominant market share (35%) due to an increasing burden of chronic diseases.
By Products
In 2023, the Enteral Feeding Formulas market was significantly dominated by the Standard Formula segment, which held more than 56.8% of the market share. These formulas serve as a staple in enteral feeding, offering a balanced blend of macronutrients, micronutrients, and calories essential for individuals who cannot consume regular food orally. Standard formulas are a common choice for patients requiring enteral feeding, especially those with no specific dietary needs or medical conditions requiring a tailored formula.
Contrarily, Disease-specific Formulas cater to individuals with particular health conditions or nutritional deficiencies. These specialized formulas are precisely formulated to meet the unique dietary requirements of patients with specific ailments, such as diabetes, renal disorders, or malabsorption issues. While Standard Formulas encompass a broader spectrum, Disease-specific Formulas address the nuanced nutritional needs of patients with distinct medical conditions, ensuring optimal dietary support for their health management.
By Flow Type
In 2023, the Enteral Feeding Formulas market was largely dominated by the Intermittent Feeding Flow segment, capturing over 89% of the market share. Intermittent feeding involves administering feedings at specific intervals during the day, allowing patients to receive nutrients over shorter periods. This method is often used for patients who can tolerate larger amounts of formula at once, aiding in better digestion and absorption of nutrients.
On the other hand, Continuous Feeding Flow involves a steady and slow infusion of feeding formula over an extended duration, typically for patients who require a continuous and slow intake of nutrients. This method is commonly used for patients who have compromised digestion or tolerance to larger volumes of feedings, requiring a gradual and continuous supply of nutrients throughout the day or night.
By Stage
In 2023, adults were the leading users of enteral feeding formulas, holding a strong market position with over 90.4% share. This dominance was driven by the high prevalence of conditions like gastrointestinal disorders and malnutrition in the adult population, necessitating specialized nutritional support.
Pediatrics, on the other hand, represented a smaller yet significant segment in the enteral feeding formulas market. Despite its comparatively smaller share, the pediatric segment exhibited notable growth due to increased awareness and diagnosis of pediatric conditions requiring enteral nutrition, such as congenital disorders or feeding difficulties in infants and children.
The distinct needs of each segment contributed to the diversification of product offerings in the market. Formulas tailored to specific age groups and health conditions gained traction, aiming to address the unique nutritional requirements of both adults and pediatric patients. This segmentation allowed for targeted development and marketing strategies to cater to the specialized needs of each demographic.
By Indication
In 2023, the “Others” category emerged as a dominant force in the enteral feeding formulas market, securing over 37% of the share. This catch-all category encompasses a diverse range of indications not specifically outlined in other segments, such as specialized dietary needs or unique medical conditions that require enteral nutrition support but don’t fall under defined categories.
Among the defined segments, cancer care held a substantial market share owing to the widespread use of enteral feeding formulas in managing the nutritional challenges associated with cancer treatment. Similarly, Alzheimer’s, diabetes, and chronic kidney diseases constituted significant segments, highlighting the growing recognition of enteral nutrition’s role in supporting patients with these conditions.
Indications like dysphagia, malabsorption/GI disorders/diarrhea, and orphan diseases represented smaller yet noteworthy segments. These areas witnessed increased attention due to heightened awareness, improved diagnosis, and the development of specialized formulas tailored to address the unique nutritional needs arising from these conditions.
Each indication segment drove innovation and product development, focusing on formulating specialized enteral feeding solutions to cater to the distinct dietary requirements of patients with specific health conditions. This segmentation facilitated targeted approaches in research, development, and marketing efforts to address the diverse needs of patients across various medical indications.
By Sales Channel
In 2023, Institutional Sales took the lead in the enteral feeding formulas market, commanding over 51.6% of the share. This dominance stemmed from the significant utilization of enteral nutrition in hospitals, clinics, and other healthcare institutions where patients require specialized nutritional support under medical supervision.
Retail Sales emerged as another substantial segment, reflecting the convenience and accessibility of enteral feeding formulas for consumers seeking these products through pharmacies, supermarkets, and specialty health stores. The retail channel gained traction due to the rising awareness of enteral nutrition’s benefits among individuals caring for family members at home and seeking easily accessible options.
Online Sales constituted a smaller yet growing segment, driven by the increasing trend of e-commerce platforms offering a wide range of enteral feeding formulas. This channel appealed to consumers seeking convenience, diverse product choices, and doorstep delivery, especially for those managing long-term nutritional requirements.
Each sales channel had its unique strengths, catering to different consumer preferences and needs. Institutional sales dominated due to the critical role of healthcare facilities in managing patients requiring enteral nutrition, while retail and online sales channels offered flexibility and accessibility for consumers seeking these products for home use or caretaking purposes. The market segmentation by sales channels facilitated varied distribution strategies to ensure convenient access for consumers across different purchasing preferences.
By End-use
In 2023, Home Care emerged as the dominant sector in the enteral feeding formulas market, securing over 61.4% of the share. This significant dominance reflects the increasing trend of managing enteral nutrition needs in a home setting, where patients receive specialized feeding formulas under the guidance of healthcare professionals or caregivers.
Hospitals, while a vital segment, represented a smaller share compared to home care. They continued to play a crucial role in providing enteral feeding solutions, particularly in critical care units (ICUs), oncology, neurology, and cardiology departments where patients require intensive medical support and monitoring.
Among specialized medical fields, critical care (ICU) and oncology held substantial shares, emphasizing the critical role of enteral nutrition in supporting patients undergoing intensive treatments or dealing with complex medical conditions.
The dominance of home care indicates a growing preference for managing enteral nutrition outside traditional healthcare settings, driven by factors such as the desire for patient comfort, cost-effectiveness, and advancements in technology that enable effective home-based nutritional support.
The segmentation by end-use highlights the evolving landscape of enteral feeding practices, with a notable shift towards home-based care alongside the continued importance of hospitals and specialized medical departments in providing crucial nutritional support to patients with varying medical needs.
*Actual Numbers Might Vary In The Final Report
Key Market Segments
By Product
- Standard Formula
- Disease-specific Formulas
By Flow Type
- Intermittent Feeding Flow
- Continuous Feeding Flow
By Stage
- Adults
- Pediatrics
By Indication
- Alzheimer’s
- Nutrition Deficiency
- Cancer Care
- Diabetes
- Chronic Kidney Diseases
- Orphan Diseases
- Dysphagia
- Pain Management
- Malabsorption/GI Disorder/Diarrhea
- Others
By End-use
- Hospitals
- Cardiology
- Neurology
- Critical Care (ICU)
- Oncology
- Home Care
By Sales Channel
- Online Sales
- Retail Sales
- Institutional Sales
Drivers
Increasing incidence of cancer
Enteral nutritional formulas are a form of nutrition used to provide essential nutrients to individuals with cancer or other diseases that make it difficult for them to eat or digest food. These formulas, which can be taken orally or through a feeding tube, are designed to provide the necessary nutrition for individuals who cannot get proper nutrition from regular food or cannot take in enough calories and nutrients from regular food alone.
Enteral nutrition is becoming more popular due to the increasing number of cancer patients who need nutritional support. As cancer cases continue to rise, the demand for enteral nutrition will also increase. Additionally, enteral nutrition has been found to reduce the risk of infection in cancer patients and other complications associated with chemotherapy, radiation, and surgery. This has led to more physicians prescribing enteral nutrition to their patients.
The rise in cancer patients has also increased the demand for enteral formulas containing specialized ingredients. For example, some formulas are designed to provide the necessary nutrition for individuals undergoing chemotherapy or radiation therapy, while others are designed to provide essential nutrients to individuals with weakened immune systems. Furthermore, the market for enteral nutrition formulas is expected to be further boosted by new developments in the field.
Increased prevalence of diabetes
The increasing prevalence of diabetes is driving the growth of the enteral feeding formula market. As the elderly population continues to rise, the need for enteral feeding formulas has also increased. This is because many elderly patients with type-2 diabetes are at increased risk for microvascular and microvascular complications. To maintain glycemic control, many patients require an enteral feeding formula to supplement their nutrition when oral feeding is inadequate.
Along with the aging population, the increasing prevalence of diabetes also contributes to the market’s growth. Unhealthy lifestyles, such as having a poor diet, have been linked to the rising incidence of diabetes, further driving the demand for enteral feeding formulas.
Additionally, one of the primary drivers of regional development is the rise in preterm births in Asian nations. These are some of the major factors propelling the market growth.
Restraints
The lack of awareness among both medical professionals and patients regarding enteral feeding poses a significant restraint on the market’s growth. Studies, such as the one focusing on patients with advanced dementia, highlight the limited understanding among doctors regarding the appropriate indications for using feeding tubes (FTs) in such cases. The findings revealed that a mere 17.9% of doctors recognized that FTs have no indications for patients with advanced dementia, indicating substantial gaps in knowledge within the medical community.
Furthermore, despite the availability of established clinical guidelines concerning enteral feeding for critically ill patients, there remains a considerable disparity between these recommendations and actual nutrition practices. This discrepancy underscores the challenge of implementation and adherence to established protocols in healthcare settings, leading to suboptimal nutrition practices and potential underfeeding, which is a global concern.
Addressing this restraint necessitates an enhanced focus on standardizing and implementing systematic enteral nutrition (EN) training within hospital departments. Additionally, the provision of dedicated full-time nutritionists in intensive care units (ICUs) and the rational allocation of medical resources and personnel are crucial. By strengthening these aspects of healthcare delivery, there is potential to mitigate the gaps in knowledge, improve adherence to established guidelines, and ensure more effective enteral feeding practices, consequently minimizing restraints on the market’s growth.
Opportunities
Over the past 25 years, the landscape of enteral feeding formulas has seen a remarkable evolution, marked by a significant increase in both the number and diversity of available products. With over 1,000 formulas now accessible, companies are actively introducing innovative products to meet the diverse needs of clients. An exemplary instance of this innovation is Abbott’s introduction of PediaSure Harvest and Ensure Harvest in 2019. These products, incorporating real-food ingredients sourced from mango, spinach, carrot, pumpkin, and banana, were developed specifically to address the demand for nourishing food blends tailored for tube-fed patients.
Recent studies have illuminated the need for high-protein enteral nutrition formulas to meet the increased energy requirements of critically ill individuals, creating a market opportunity. Furthermore, continuing advances in our understanding of disease physiology, food ingredient composition and functionality open doors for further innovations in enteral feeding formulas.
These opportunities signify robust growth potential for companies operating in this sector. The ability to introduce new products that cater to diverse nutritional needs, including high-protein formulas and blends featuring real-food ingredients, aligns with the evolving demands of both healthcare professionals and patients. Further innovation in formulation and ingredients based on expanding scientific knowledge presents a promising path for sustained growth and development within the enteral feeding formulas market.
Challenges
Clogging of Enteral Tubes
When large amounts of enteral food, fillers, and medications are administered via comparatively tiny PEG tubes, it frequently results in blockages. Enteral feeding tubes are used in many medical settings to deliver nutrition to individuals who cannot eat or drink independently. These tubes are inserted through the nose or mouth and are designed to deliver nutrition directly to the stomach or small intestine.
Although enteral feeding tubes are a reliable and efficient way to provide nutrition to patients, they can be prone to obstruction or blockages. Blockages may occur when too thick foods or medications are administered through relatively small feeding tubes.
Additionally, gastric juice can coagulate and clog the tube due to its low pH value. If a blockage is not identified and cleared promptly, it can lead to serious medical issues such as undernutrition or even death. To prevent blockages or obstructions, it is important to be mindful of the type and consistency of food administered through the feeding tube.
Additionally, radiographic confirmation is an effective and reliable way to determine the existence of a blockage, but it increases the cost of care and exposes the patient to additional radiation. It is also important to avoid repeated gastric aspirations as this can lead to blockages.
Regional Analysis
The enteral nutrition market can be segmented geographically into North America, Europe, Asia-Pacific, South America, and Middle-East & Africa. In 2022, North America held a dominant market share of 35%, largely attributed to the increasing burden of chronic diseases such as diabetes, cancer, and other neurological disorders. In addition, the frequency of premature births has increased in the region, and according to the Center for Disease Prevention and Control (SPKC) data, the number of premature births will increase by 4% by 2021.
However, Asia Pacific is expected to be the fastest-growing segment due to the increasing prevalence of diabetes and cancer in the region. In addition, Asia’s population is aging faster than any other region in the world. According to a report by the Census Bureau, the number of older people in Asia is expected to nearly triple in the next four decades.
*Actual Numbers Might Vary In The Final Report
Key Regions and Countries
- North America
- The US
- Canada
- Mexico
- Europe
- Germany
- The UK
- France
- Italy
- Russia
- Spain
- Rest of Europe
- APAC
- China
- Japan
- South Korea
- India
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- MEA
- GCC
- South Africa
- Israel
- Rest of MEA
Key Players
Product launches, mergers and acquisitions, joint ventures, and geographical expansion are the primary strategies employed by the enteral formula industry players. The top 10 companies in the enteral milk formula market are
Market Key Players
- Nestle SA
- Danone SA
- Abbott Laboratories
- Mead Johnson & Company, LLC
- Hormel Foods Corporation
- Braun Melsungen AG
- Meiji Holdings Co., Ltd
- Medline Industries, Inc
- Medtrition, Inc.
- Victus, Inc.
- Other Key Players
Key Developments
In September 2023, Abbott announced the plan to boost the manufacturing of various adult enteral formulas for the retail market to counteract low supply in the institutional sector.
In February 2022, Nestlé (Switzerland) agreed to purchase a majority stake in Orgain, a leader in plant-based nutrition. This acquisition would complement Nestlé Health Science’s existing portfolio of nutrition products
In September 2022, Kate Farms introduced Adult Standard 1.4, a high-calorie medical formula now offered in chocolate. This product is designed to assist in weight gain, weight maintenance, and improved tolerance while providing a delicious taste
Report Scope
Report Features Description Market Value (2023) USD 7.2 Billion Forecast Revenue (2033) USD 12.3 Billion CAGR (2024-2033) 5.5% Base Year for Estimation 2023 Historic Period 2017-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered By Product(Standard Formula, Disease-specific Formulas), By Flow Type(Intermittent Feeding Flow, Continuous Feeding Flow), By Stage(Adults, Pediatrics), By Indication (Alzheimer’s, Nutrition Deficiency, Cancer Care, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, Others), By End-use(Hospitals, Cardiology, Neurology, Critical Care (ICU), Oncology, Home Care), By Sales Channel(Online Sales, Retail Sales, Institutional Sales), By Product(Standard Formula, Disease-specific Formulas), By Flow Type(Intermittent Feeding Flow, Continuous Feeding Flow), By Stage(Adults, Pediatrics, By Indication, Alzheimer’s, Nutrition Deficiency, Cancer Care, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, Others), By End-use(Hospitals, Cardiology, Neurology, Critical Care (ICU), Oncology, Others, Home Care), By Sales Channel(Online Sales, Retail Sales, Institutional Sales) Regional Analysis North America-US, Canada, Mexico;Europe-Germany, UK, France, Italy, Russia, Spain, Rest of Europe;APAC-China, Japan, South Korea, India, Rest of Asia-Pacific;South America-Brazil, Argentina, Rest of South America;MEA-GCC, South Africa, Israel, Rest of MEA Competitive Landscape Nestle SA, Danone SA, Abbott Laboratories, Mead Johnson & Company, LLC, Hormel Foods Corporation, Braun Melsungen AG, Meiji Holdings Co., Ltd, Medline Industries, Inc, Medtrition, Inc., Victus, Inc., Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
What are enteral feeding formulas?Enteral feeding formulas are specialized liquid nutritional products designed to be delivered directly into the gastrointestinal tract for individuals who cannot consume food orally or have difficulty absorbing nutrients.
How important is innovation in this market?Innovation is crucial for developing formulas that cater to different patient needs, improve absorption rates, reduce side effects, and enhance overall patient well-being.
What are the nutritional benefits of enteral feeding formulas?These formulas provide essential nutrients, vitamins, minerals, proteins, fats, and carbohydrates in a balanced form, meeting the nutritional requirements of individuals who cannot take in food normally.
Enteral Feeding Formulas MarketPublished date: Dec 2023add_shopping_cartBuy Now get_appDownload Sample - Nestlé S.A Company Profile
- Danone SA
- Abbott Laboratories
- Mead Johnson & Company, LLC
- Hormel Foods Corporation
- B. Braun Melsungen AG Company Profile
- Meiji Holdings Co., Ltd
- Medline Industries, Inc
- Medtrition, Inc.
- Victus, Inc.
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |